The Protein Expression and Libraries Facility (Protein Expression) provides Cancer Center members efficient and expert technical assistance in recombinant DMA plasmid engineering, protein expression in bacteria and baculovirus-infected insect cells, purification of recombinant proteins to homogeneity, and production of high-titer stocks of retroviruses (e.g. lentiviruses) for delivery of shRNA and cDNAs to mammalian cells. The Facility has expertise in all aspects of vector technology for protein expression, baculovirus generation, recombinant protein expression, and affinity and conventional chromatography approaches to protein purification, and production of infectious lenti-/retroviruses. The proteins produced by the facility must be of high quality and purity in order to be used by Cancer Center scientists to achieve a wide range of experimental objectives, such as characterization of enzymatic activities, crystallization for structural analysis, characterization of structure-function relationships of protein:protein, protein:nucleic acid, and protein:small molecule interactions;development of assays for small molecule high throughput screening;and immunization of mice to generate custom antibodies utilizing the Hybridoma Facility. The facility will continue to expand it's repertoire of vectors available for protein expression, included high titer retroviral vectors, acquire RNAi libraries, and implement a new assay development service for highthroughput screening of small molecule libraries. The facility personnel are highly trained technical experts in all areas of the proposed support services to be provided to the individual projects. The centralization and standardization of these practices under the direction of very experienced staff allows for high-throughput expression plasmid construction and large-volume protein expression services, including quality assurance and control procedures to ensure efficient, consistent production and purification of high quality recombinant proteins. The Facility also maximizes biosafety by confining retrovirus (e.g. lentivirus) production to a centralized biosafety level 2 (BSL2) unit, which prevents aerosolization of viruses from contaminating incubators and parental cultures of cell lines, and improves quality control in the production of virus stocks to be used in gain- and loss-of-function experiments in vitro and in vivo. Currently the Facility is being expanded to accommodate the storage and handling of viral libraries, additional purification instruments, and the rapid assay systems to meet Cancer Center needs.

Public Health Relevance

Recombinant DMA technology has provided the unique opportunity to produce otherwise rare proteins derived from recombinant genes. The availability of these proteins has enabled many types of experiments that would have otherwise been impossible. Also, the facility will provide and manage libraries of shRNA genes in lenteviral vectors that can be used to manipulate the expression of genes for cancer research.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Tomescu, Costin; Tebas, Pablo; Montaner, Luis J (2017) IFN-? augments NK-mediated antibody-dependent cellular cytotoxicity (ADCC) of HIV-1 infected autologous CD4+ T cells regardless of MHC-I downregulation. AIDS :
Vitiello, Marianna; Tuccoli, Andrea; D'Aurizio, Romina et al. (2017) Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8:25395-25417
Veglia, Filippo; Gabrilovich, Dmitry I (2017) Dendritic cells in cancer: the role revisited. Curr Opin Immunol 45:43-51
Hoffman, Hunter; Rice, Cory; Skordalakes, Emmanuel (2017) Structural Analysis Reveals the Deleterious Effects of Telomerase Mutations in Bone Marrow Failure Syndromes. J Biol Chem 292:4593-4601
Lu, Fang; Wiedmer, Andreas; Martin, Kayla A et al. (2017) Coordinate Regulation of TET2 and EBNA2 Control DNA Methylation State of Latent Epstein-Barr Virus. J Virol :
Karpel-Massler, Georg; Ishida, Chiaki Tsuge; Bianchetti, Elena et al. (2017) Inhibition of Mitochondrial Matrix Chaperones and Antiapoptotic Bcl-2 Family Proteins Empower Antitumor Therapeutic Responses. Cancer Res 77:3513-3526
Lynch, Shannon M; Mitra, Nandita; Ravichandran, Krithika et al. (2017) Telomere Length and Neighborhood Circumstances: Evaluating Biological Response to Unfavorable Exposures. Cancer Epidemiol Biomarkers Prev 26:553-560
Perales-Puchalt, Alfredo; Svoronos, Nikolaos; Rutkowski, Melanie R et al. (2017) Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target. Clin Cancer Res 23:441-453
Pestell, Timothy G; Jiao, Xuanmao; Kumar, Mukesh et al. (2017) Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth. Oncotarget 8:81754-81775
Noguchi, Shuhei; Arakawa, Takahiro; Fukuda, Shiro et al. (2017) FANTOM5 CAGE profiles of human and mouse samples. Sci Data 4:170112

Showing the most recent 10 out of 685 publications